Dr. Chryssostomos Chatgilialoglu was appointed Director of the Institute of Nanoscience and Nanotechnology (INN) in the NCSR “Demokritos”, Athens, in March 2014. He is also the Honorary President and Co-founder of spin-off companies Lipinutragen (Italy) and Lipinutramed (Greece). He chaired the COST Action CM0603 on Free Radicals in Chemical Biology, from 2007 to 2011, and is now the Chairman of the COST Action CM1201 on Biomimetic Radical Chemistry, running from 2012 to 2016. In 1976, he received his doctorate degree in Industrial Chemistry from the University of Bologna and completed his postdoctoral studies at York University (UK) and National Research Council of Canada, Ottawa. From 1983, he worked for the Consiglio Nazionale delle Ricerche (Bologna), and was Research Director from 1991 to 2014. He has received many honors and awards including the Fluka Prize “Reagent of the Year 1990”, and is a world-expert in free radicals. He has published over 240 papers in peer-reviewed international journals (>7,500 citations, h-index 43), 33 book chapters, 6 patents, and 7 books (3 as author and 4 edited); Co-Editor of the Encyclopedia of Radical in Chemistry, Biology and Materials (4 volumes), 2012 John Wiley & Sons, Ltd. Over 100 invited lectures at international conferences and over 120 invited research seminars at institutions.

Lipidomics

Dr. Alejandro Gugliucci is a founding faculty member at Touro University, California, USA which he joined in 1997. He earned his MD and Board Certification in Laboratory Medicine from the University of the Republic, Uruguay. He obtained his PhD in Biochemistry at the University Louis Pasteur of Strasbourg, France. His postdoctoral fellowship in Cell Biology was carried out at the University of Montreal, Canada, where he also worked a few years as a faculty member before moving to the USA. In his alma mater he was a professor in the Biochemistry and Clinical Pathology departments where he was Head of the Lipoprotein Metabolism division at 20-floor, 800 bed hospital for more than 10 years. He was a visiting professor in Tokyo Juntendo University and Niigata Medical School, Japan in 1998 and at the University of Sao Paulo, Brazil in 2007. He has been Full Professor of Biochemistry for the past 8 years. He served as COM Research Director then Associate Dean for Research for the past 10 years leading the exponential growth of research at TUC, the most significant in the Touro College system. He has been recently appointed as University Director of Research Development and Sponsored Programs.

Diabetes mellitus and lipoprotein metabolism.

Nathan D. Wong, PhD is Professor and Director of the Heart Disease Prevention Program in the Division of Cardiology at University of California, Irvine School of Medicine. He is also Adjunct Professor of Epidemiology at UC Irvine and UCLA. Holding PhD and MPH degrees in epidemiology from Yale University, he is also a Fellow of the American College of Cardiology and the American Heart Association Council on Epidemiology and Prevention. He is Immediate Past President of the American Society for Preventive Cardiology. Dr. Wong has been an investigator or collaborator with numerous large-scale NIH-sponsored studies including the Framingham Heart Study, Women’s Health Initiative, Antihypertensive Lipid-Lowering to Prevent Heart Attack Trial, and the Multiethnic Study of Atherosclerosis. He regularly lectures nationally and internationally on his research in various topics in preventive cardiology and is a member of Who’s Who in America and Who’s Who in the World. With over 20 years of experience as a cardiovascular epidemiologist, Dr. Wong has edited or co-edited four clinical references. He has also authored or co-authored over 200 peer-reviewed manuscripts in his principal research areas of subclinical atherosclerosis, metabolic syndrome, diabetes, and lipids and hypertension, and serves on the editorial boards of several noted journals in the areas of cardiovascular disease and diabetes.

cardiovascular disease and diabetes

Dr. Siddiqui was born on December 1, 1960 in Karachi, Pakistan where he received his early school education. Dr. Siddiqui earned his B.Sc. (1978), M.Sc. (1980) degrees in Biochemistry from the University of Karachi, Karachi, Pakistan. Dr. Siddiqui was accepted as a candidate for PhD studies by University of Oxford, UK, University of Calgary, Canada and University of North Carolina, USA, but he decided to accept a prestigious scholarship from the Australian National University, Canberra, Australia where he obtained his PhD in 1988. During his PhD he investigated the metabolic basis of cancer cachexia under the supervision of Professor John F. Williams, who is famous for his research on the pentose phosphate pathway. He served as a postdoctoral fellow (1987-1989) in Dr. Stuart McCutcheons (Currently Vice Chancellor Auckland University, New Zealand) laboratory at Massey University, Palmerton North, New Zealand. Dr. Siddiqui immigrated to America in 1989 on an invitation from Dr. John Exton on a Howard Hughes fellowship at Vanderbilt University Medical Center, Vanderbilt University, Nashville. Dr. Siddiqui Started his research work in the Bone Marrow Transplant Research Laboratory at Methodist Hospital in 1993. He established his independent research laboratory in 1999 and at present he is a Senior Investigator and Director of the Cellular Biochemistry Research Laboratory at the Methodist Research Institute. Dr. Siddiqui also has adjunct appointments in the Department of Biology, Indiana University-Purdue University, and Department of Medicine, Indiana University Medical School, Indianapolis. Dr. Siddiqui's research interests are in the area of cancer, inflammation and cardiovascular diseases. His research emphasis is on modulation of diseases by dietary fatty acids such as omega-3, omega-6 omega-9 and trans fatty acids. Dr. Siddiqui has received funding from National Cancer Center (NIH), American Heart Association, Showalter Foundation, Abbott Pharmaceuticals, and Baxter Nutrition.

cancer, inflammation and cardiovascular diseases

More than 20 years of renowned scientists and physicians led Prof. Dr. Raimund Erbel successfully the Department of Cardiology at the University Hospital Essen (Essen University). Now the clinic director leaves the West German Heart and Vascular Center Essen and will be retired. In his farewell lecture on Friday, July 31, 2015, 15.15 clock, invites the Dean Prof. Dr. Jan Buer not only members and students of the Medical Faculty of the University of Duisburg-Essen (UDE), but also the citizens of the city of Essen as well as all friends University cordially in the main auditorium of the UDE, Universitätsstraße 2, Campus Essen, a. The title of the farewell lecture is: "The road to cardiology 2015-45 years of heart and circulatory medicine in fast motion". His academic career began Prof. Raimund Erbel at the University of Dusseldorf, where he received his doctorate 1974th After his interns time in Leverkusen and activities at the University Hospital in Dusseldorf and at the Bundeswehr Central Hospital Koblenz, he moved 1977 RWTH Aachen. There he received his Specialist in internal medicine and cardiology. After his move to Mainz in 1982, he was appointed 1988 Professor for Life. In 1993, Prof. Raimund Erbel then the reputation of the former University of Essen to build the cardiology at University Hospital Essen.

internal medicine and cardiology

After his graduation in 1950 in Bludenz studied Spiteller at the University of Innsbruck chemistry. In 1956 he was in Innsbruck for Dr. phil. doctorate. Then he had to 1958 in Innsbruck, a postdoctoral fellow at the Department of Organic Chemistry. He synthesized the Breitbandsulfonamid there sulphadimethoxine (Madribon). He then moved to the University of Vienna in the working group of Friedrich Wessely. This was followed by a two-year postdoctoral stay (1960-1961) at the Massachusetts Institute of Technology. One area was about the structural elucidation of indole alkaloids, such as quebrachamine, by means of mass spectrometry (MS). 1961 went Spiteller back to Vienna and worked as a research assistant at the Institute of Organic Chemistry. His field there was the structure elucidation of alkaloids, steroids and metabolites of drugs and mass spectroscopy. 1964 Spiteller was in Vienna habilitated. In 1965 he went as a Scientific Council and C2 professor at the University of Göttingen, where he continued his research on the structure elucidation of natural products by MS. In 1969 he became C3 professor and started a new field of work: the study of the relationships between diseases and consequent changes in metabolism. 1975 received Spiteller in Göttingen a C4 professorship, but was followed in the same year a call to the newly established University of Bayreuth. In Bayreuth, he worked on the structure elucidation and biogenesis of furanoid fatty acids and discovered 1980 Urofuransäuren as metabolites of furanoid fatty acids.Oxidized fatty acids, their decomposition products and their physiological effects are among the other work areas Spitellers.

furanoid fatty acids

Carl E. Freter, MD, PhD, FACP is the Director of the Division of Hematology and Oncology at Saint Louis University. He is a tenured Professor of Medicine, Associate Director of the Saint Louis University Cancer Center and the Rosalie Fusz Endowed Chair of Hematology. Dr. Freter is also the Director of the Fellowship Program in Hematology and Oncology. Dr. Freter received his MD and PhD in biochemistry at Washington University School of Medicine. He did his internship and residency training at Stanford University, and his fellowship in hematology/oncology at the National Cancer Institute at the NIH. Before coming to Saint Louis University in 2014, Dr. Freter was the Co-Director of the Ellis Fischel Cancer Center at the University of Missouri-Columbia, as well as the Director of the Division of Hematology and Oncology and the Fellowship Program in Hematology and Oncology. He is one of America’s Top Oncologists and for the last 4 years, been featured in St. Louis Magazine’s Annual Best Doctors of St. Louis issue. He is a member of the American College of Physicians, American Association of Cancer Research, American Society of Clinical Oncology, and American Society of Hematology. In 2014, Dr. Freter was honored at the annual Leukemia/Lymphoma Meeting in St. Louis for assistance in testimony in the passing or the oral chemotherapy parity bill in the state of Missouri. Dr. Freter’s areas of expertise in both clinical and research areas include breast cancer, malignant hematology, leukemia and lymphoma. He has two research laboratories at Saint Louis University engaged in anti-cancer research. Dr. Freter is the President and CEO of his own biotech start-up company, ONCOLYSIS, LLP. He has authored multiple book chapters and articles in peer reviewed journals. He has presented at many international and national conferences and has participated in NIH and industry sponsored research projects. Dr. Freter has received NIH funding on multiple research projects and funding from multiple other outside sources for conducting cancer research.

Identifying new anticancer drugs by making alterations in lipid metabolism in cancer cells